Preventing cardiovascular disease in women
- PMID: 17087427
Preventing cardiovascular disease in women
Abstract
Cardiovascular disease (CVD) has been the primary cause of death in women for almost a century, and more women than men have died of CVD every year since 1984. Although CVD incidence can be reduced by adherence to a heart-healthy lifestyle and detection and treatment of major risk factors, preventive recommendations have not been consistently or optimally applied to women. The American Heart Association guidelines for CVD prevention in women provide physicians with a clear plan for assessment and treatment of CVD risk and personalization of treatment recommendations. The emphasis of preventive efforts has shifted away from treatment of individual CVD risk factors in isolation toward assessment of a woman's overall or "global" CVD risk. In addition to accounting for the presence or absence of preexisting coronary heart disease or its equivalents (e.g., diabetes, chronic kidney disease), cardiovascular risk can be further calculated with the Framingham risk score, which is based on age, sex, smoking history, and lipid and blood pressure levels. Intervention intensity and treatment goals are tailored to overall risk, with those at highest risk receiving the most intense risk-lowering interventions. Women at high risk for CVD and without contraindications should receive aspirin, beta blockers, and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in addition to pharmacologic therapy for hyperlipidemia, hypertension, and diabetes. Women who already are at optimal or low risk for CVD should be encouraged to maintain or further improve their healthy lifestyle practices. Optimal application of these preventive practices significantly reduces the burden of death and disability caused by heart attack and stroke in women.
Comment in
-
The heart of women's health.Am Fam Physician. 2006 Oct 15;74(8):1285-6. Am Fam Physician. 2006. PMID: 17087423 No abstract available.
Similar articles
-
National study of physician awareness and adherence to cardiovascular disease prevention guidelines.Circulation. 2005 Feb 1;111(4):499-510. doi: 10.1161/01.CIR.0000154568.43333.82. Circulation. 2005. PMID: 15687140
-
Waist circumference predicts cardiometabolic and global Framingham risk among women screened during National Woman's Heart Day.J Womens Health (Larchmt). 2006 Jan-Feb;15(1):24-34. doi: 10.1089/jwh.2006.15.24. J Womens Health (Larchmt). 2006. PMID: 16417415
-
Knowledge and risk of cardiovascular disease in rural Alabama women.J Am Acad Nurse Pract. 2008 Jun;20(6):333-8. doi: 10.1111/j.1745-7599.2008.00326.x. J Am Acad Nurse Pract. 2008. PMID: 18588661
-
[Guideline 'Cardiovascular Risk Management'].Ned Tijdschr Geneeskd. 2007 May 12;151(19):1068-74. Ned Tijdschr Geneeskd. 2007. PMID: 17552415 Review. Dutch.
-
Cardiovascular disease prevention tailored for women.Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1123-34. doi: 10.1586/14779072.6.8.1123. Expert Rev Cardiovasc Ther. 2008. PMID: 18793115 Review.
Cited by
-
Effectiveness of letters to patients with or without Cochrane blogshots on 10-year cardiovascular risk change among women in menopausal transition: 6-month three-arm randomized controlled trial.BMC Med. 2022 Oct 20;20(1):381. doi: 10.1186/s12916-022-02555-2. BMC Med. 2022. PMID: 36261832 Free PMC article. Clinical Trial.
-
Gender differences in mortality among ST elevation myocardial infarction patients in Malaysia from 2006 to 2013.Ann Saudi Med. 2018 Jan-Feb;38(1):1-7. doi: 10.5144/0256-4947.2018.1. Ann Saudi Med. 2018. PMID: 29419522 Free PMC article.
-
Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndrome.Hippokratia. 2011 Oct;15(4):323-6. Hippokratia. 2011. PMID: 24391413 Free PMC article.
-
Sex-related changes in cardiac function following myocardial infarction in mice.Am J Physiol Regul Integr Comp Physiol. 2008 Aug;295(2):R528-34. doi: 10.1152/ajpregu.90342.2008. Epub 2008 Jun 11. Am J Physiol Regul Integr Comp Physiol. 2008. PMID: 18550865 Free PMC article.
-
Are there sex differences among colorectal cancer patients in treatment and survival? A Swiss cohort study.J Cancer Res Clin Oncol. 2021 May;147(5):1407-1419. doi: 10.1007/s00432-021-03557-y. Epub 2021 Mar 4. J Cancer Res Clin Oncol. 2021. PMID: 33661394 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical